Schalk Enrico, Hanus Lynn, Färber Jacqueline, Fischer Thomas, Heidel Florian H
Department of Haematology and Oncology, Medical Centre, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany,
Ann Hematol. 2015 Sep;94(9):1451-6. doi: 10.1007/s00277-015-2387-y. Epub 2015 May 3.
The aim of this study was to predict the probability of central venous catheter-related bloodstream infections (CRBSIs) in patients with haematologic malignancies using a modified version of the Infection Probability Score (mIPS). In order to perform a prospective, mono-centric surveillance of complications in clinical routine due to short-term central venous catheters (CVCs) in consecutive patients receiving chemotherapy from March 2013 to September 2014, IPS was calculated at CVC insertion and removal (mIPSin and mIPSex, respectively). We used the 2012 Infectious Diseases Working Party of the German Society of Haematology and Medical Oncology (AGIHO/DGHO) criteria to define CRBSI. In total, 143 patients (mean 59.5 years, 61.4 % male) with 267 triple-lumen CVCs (4044 CVC days; mean 15.1 days, range 1-60 days) were analysed. CVCs were inserted for therapy of acute leukaemia (53.2 %), multiple myeloma (24.3 %) or lymphoma (11.2 %), and 93.6 % were inserted in the jugular vein. A total of 66 CRBSI cases (24.7 %) were documented (12 definite/13 probable/41 possible). The incidence was 16.3/1000 CVC days (2.9/3.1/10.1 per 1000 CVC days for definite/probable/possible CRBSI, respectively). In CRBSI cases, the mIPSex was higher as compared to cases without CRBSI (13.1 vs. 7.1; p < 0.001). The best mIPSex cutoff for CRBSI prediction was 8 points (area under the curve (AUC) = 0.77; sensitivity = 84.9 %, specificity = 60.7 %, negative predictive value = 92.4 %). For patients with an mIPSex ≥8, the risk for a CRBSI was high (odds ratio [OR] = 5.9; p < 0.001) and even increased if, additionally, CVC had been in use for about 10 days (OR = 9.8; p < 0.001). In case other causes of infection are excluded, a mIPSex ≥8 and duration of CVC use of about 10 days predict a very high risk of CRBSI. Patients with a mIPSex <8 have a low risk of CRBSI of 8 %.
本研究的目的是使用改良版感染概率评分(mIPS)预测血液系统恶性肿瘤患者发生中心静脉导管相关血流感染(CRBSI)的概率。为了对2013年3月至2014年9月连续接受化疗的患者因短期中心静脉导管(CVC)导致的并发症进行前瞻性单中心监测,在CVC置入和拔除时分别计算IPS(分别为mIPSin和mIPSex)。我们采用德国血液学和医学肿瘤学会传染病工作组(AGIHO/DGHO)2012年的标准来定义CRBSI。总共分析了143例患者(平均年龄59.5岁,61.4%为男性),他们共置入了267根三腔CVC(4044个CVC日;平均15.1天,范围1 - 60天)。CVC用于急性白血病(53.2%)、多发性骨髓瘤(24.3%)或淋巴瘤(11.2%)的治疗,93.